Simcere Pharma
Simcere Pharma is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market.
Launch date
Employees
Market cap
CAD2.6b
Enterprise valuation
CAD2.4b (Public information from Sep 2024)
Share price
HKD6.16 2096.HK
China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 4.5b | 5.0b | 6.3b | 6.6b | 958m | 1.1b | 1.3b |
| % growth | (10 %) | 11 % | 26 % | 5 % | (86 %) | 14 % | 14 % |
| EBITDA | 788m | 940m | 1.1b | 1.1b | 192m | 235m | 274m |
| % EBITDA margin | 17 % | 19 % | 17 % | 17 % | 20 % | 21 % | 22 % |
| Profit | 670m | 1.5b | 933m | 715m | 131m | 173m | 208m |
| % profit margin | 15 % | 30 % | 15 % | 11 % | 14 % | 16 % | 17 % |
| EV / revenue | 0.7x | 0.6x | 0.6x | 0.3x | 1.7x | 1.4x | 1.2x |
| EV / EBITDA | 3.8x | 3.1x | 3.5x | 2.0x | 8.4x | 6.5x | 5.3x |
| R&D budget | 1.1b | 1.4b | 1.7b | 1.6b | - | - | - |
| R&D % of revenue | 25 % | 28 % | 27 % | 24 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Growth Equity VC | |
| N/A | N/A | IPO | |
* | $135m Valuation: $1.2b 1.3x EV/LTM Revenues 7.8x EV/LTM EBITDA | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Simcere Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
